Jul. 17 at 4:53 PM
$OKYO Yesterday’s RNS from OKYO Pharma didn’t spark much excitement in the market for a few key reasons:
---
### 1. **The news was already priced in**
OKYO had been preparing investors with early Phase 2 data hints, so Tuesday’s detailed release (75% response, significant pain reduction by Week 4) didn’t surprise many. With expectations already built into the price, there was limited upside. ([Investing.com Canada][1])
### 2. **Clinical landscape and milestone predictability**
While the results are positive, Phase 2 readouts aren’t rare in biotech. Investors often await Phase 3 data or regulatory milestones. Reports highlighted the outcomes as solid—but not breakthrough—so the market response was muted. 
### 3. **Share price momentum had already preceded the news**
OKYO shares had climbed \~8–14% earlier in the day, suggesting an intraday run-up. That left little room for further upside, as early buyers had already reacted. 
